AMGN May 2024 215.000 put
| Previous close | 0.1400 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 215.00 |
| Expiry date | 2024-05-10 |
| Day's range | 0.1000 - 0.1400 |
| Contract range | N/A |
| Volume | |
| Open interest | 13 |
- Yahoo Finance Video
US added 175,000 jobs in April, Apple’s stock rallies on earnings: Yahoo Finance
The April employment report shows signs the US labor market may be cooling. The US added 175,000 jobs last month, fewer than the 240,000 jobs economists had been expecting. The unemployment rate ticked higher to 3.9% from 3.8%. One of the biggest movers on Wall Street is Apple (AAPL). The tech giant posted better-than-expected sales in China and authorized a massive $110 billion share buyback plan. Other trending tickers on Yahoo Finance include Coinbase Global (COIN), Amgen (AMGN), and Block (SQ). Top guests today include:8:30 a.m. ET - Robert Sockin, Citi Senior Global Economist and Dan Gerard, State Street Global Markets, Senior Global Multi-Asset Strategist9:05 a.m. ET - Satyam Panday, S&P Global Ratings Chief US Economist9:10 a.m. ET - Martin Yang, Oppenheimer Senior Analyst of Emerging Technologies and Services9:40 a.m. ET - Acting Labor Secretary Julie Su10:20 a.m. ET - Evan Tindell, Bireme Capital co-founder and Chief Investment Office10:33 a.m. ET - Jason Robins, DraftKings CEO11:05 a.m. ET - Phil Orlando, Federated Hermes Chief Equity Strategist
- Yahoo Finance Video
Amgen, DraftKings, Live Nation: Trending tickers
Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
BloombergAmgen Soars as CEO Touts Experimental Obesity Drug Progress
(Bloomberg) -- Amgen Inc.’s shares soared after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide. Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineApple Rallies on Upbeat Forecast, Record-Setting BuybackTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesTrump Auditions VP Picks Before Wealthy Donors
